1. Antibody-drug Conjugate/ADC Related
    Cytoskeleton
    Cell Cycle/DNA Damage
  2. Drug-Linker Conjugates for ADC
    Microtubule/Tubulin

Mertansine (Synonyms: DM1; Maytansinoid DM1; DM-1; Maytansinoid DM-1; DM 1; Maytansinoid DM 1)

Cat. No.: HY-19792 Purity: 98.22%
Data Sheet SDS Handling Instructions

Mertansine is a tubulin inhibitor,inhibits the assemblyof microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC).

For research use only. We do not sell to patients.
Mertansine Chemical Structure

Mertansine Chemical Structure

CAS No. : 139504-50-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO $143 In-stock
2 mg $55 In-stock
5 mg $88 In-stock
10 mg $150 In-stock
25 mg $300 In-stock
50 mg $520 In-stock
100 mg $940 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

Description

Mertansine is a tubulin inhibitor,inhibits the assemblyof microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC). In vitro: Maytansine is a potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at sub-nanomolar concentrations. Maytansine at a concentration of 100 nmol/L suppressed the growth and shortening rates by 35%, quantitatively similarly to the same concentration of vinblastine. maytansine inhibits the formation of a cross-link between Cys 12 and Cys 201

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01745965 West German Study Group|Roche Pharma AG Breast Cancer November 2012 Phase 2
NCT01976169 University of Texas Southwestern Medical Center|Pfizer|University of Pennsylvania Advanced Breast Cancer January 2014 Phase 1
NCT01983501 Cascadian Therapeutics Inc. HER2 Positive Breast Cancers February 2014 Phase 1
NCT02236000 NSABP Foundation Inc|Puma Biotechnology, Inc. Breast Cancer August 2014 Phase 1|Phase 2
NCT02326974 Dana-Farber Cancer Institute|Genentech, Inc. HER-2 Positive Breast Cancer|Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer December 2014 Phase 2
NCT03190967 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Breast Cancer|Brain Metastasis|Brain Cancer July 28, 2017 Phase 1|Phase 2
NCT03032107 Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp. Breast Cancer February 17, 2017 Phase 1
NCT01565200 Jules Bordet Institute|Roche Pharma AG HER-2 Positive Breast Cancer May 2012 Phase 2
NCT00932373 Genentech, Inc. Metastatic Breast Cancer April 2006 Phase 1
NCT01120561 Genentech, Inc. Metastatic Breast Cancer May 2010
NCT01835236 Swiss Group for Clinical Cancer Research Metastatic Breast Cancer April 29, 2013 Phase 2
NCT00928330 Genentech, Inc. Metastatic Breast Cancer July 2009 Phase 1
NCT02657343 Dana-Farber Cancer Institute|Novartis Breast Cancer March 9, 2016 Phase 1|Phase 2
NCT00052000 Millennium Pharmaceuticals, Inc. Prostate Cancer November 2002 Phase 1
NCT00070837 Millennium Pharmaceuticals, Inc. Prostatic Neoplasms October 2003 Phase 1|Phase 2
NCT02135159 Institut du Cancer de Montpellier - Val d'Aurelle HER2-positive Breast Cancer February 2014 Phase 1
NCT02073916 Jenny C. Chang, MD|The Methodist Hospital System Metastatic Breast Cancer October 2013 Phase 1|Phase 2
NCT01042379 QuantumLeap Healthcare Collaborative Breast Neoplasms|Breast Cancer|Breast Tumors March 2010 Phase 2
NCT02254018 Boehringer Ingelheim Head and Neck Neoplasms September 2002 Phase 1
NCT02452554 Children's Oncology Group|National Cancer Institute (NCI) Pleuropulmonary Blastoma|Recurrent Malignant Peripheral Nerve Sheath Tumor|Recurrent Neuroblastoma|Recurrent Rhabdomyosarcoma|Recurrent Synovial Sarcoma|Wilms Tumor October 2015 Phase 2
NCT02254005 Boehringer Ingelheim Breast Neoplasms October 2002 Phase 1
NCT02254031 Boehringer Ingelheim Breast Neoplasms July 2003 Phase 1
NCT02254044 Boehringer Ingelheim Carcinoma, Squamous Cell October 2003 Phase 1
NCT02420873 M.D. Anderson Cancer Center|ImmunoGen, Inc. Leukemia May 12, 2015 Phase 2
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.3545 mL 6.7724 mL 13.5448 mL
5 mM 0.2709 mL 1.3545 mL 2.7090 mL
10 mM 0.1354 mL 0.6772 mL 1.3545 mL
M.Wt

738.29

Formula

C₃₅H₄₈ClN₃O₁₀S

CAS No.

139504-50-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 83.33 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 98.22%

  • 唐冬 竞价

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Mertansine
Cat. No.:
HY-19792
Quantity: